Form 4: Edwards Lifesciences Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, executed transactions involving company stock, including the sale of 5,000 shares, under a pre-arranged 10b5-1 trading plan.
Summary
- On May 10, 2024, Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, sold 5,000 shares of common stock at a weighted average price of $87.8076.
- The sale was executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
- Bobo also exercised an employee stock option to acquire 5,000 shares at a price of $45.2767 on the same day.
- Following these transactions, Bobo directly owns 46,935.7184 shares of common stock and indirectly owns 38,615.0363 shares through a 401(k) and 135,152 shares through a trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reflects routine transactions under a pre-arranged trading plan and doesn't inherently indicate a positive or negative outlook.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 2018-06-17 | Employee Stock Option Date Exercisable |
| 2023-12-14 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-05-10 | Date of stock option exercise and stock sale |
| 2024-05-11 | Date of transaction |
| 2024-05-16 | Employee Stock Option Expiration Date |
| 2024-05-13 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.